Consensus PROCEPT BioRobotics Corporation

Stocks

PRCT

US74276L1052

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2026-10-29 EDT			5-day change	1st Jan Change
20.30 ^USD	+0.50%		+1.35%	-35.47%

10-07	Barclays Initiates PROCEPT BioRobotics at Overweight With $30 Price Target	MT
10-02	PROCEPT BioRobotics Corporation Announces Appointment of Dr. Michael Mack as Member of the Board, Effective October 2, 2026	CI

Evolution of the Average Target: PROCEPT BioRobotics Corporation

Evolution of the Target Price: PROCEPT BioRobotics Corporation

Changes in Analyst Recommendations: PROCEPT BioRobotics Corporation

b8294c0.Rp5BsTULLxfpszpXw5k10eAXBqFlr2lTeEMl5JIGV7k.cv05y0BhX3aN235gqKlRi4FnX-01lzY0QG5_1cdxIPYh6hHlRmdreJzLXQ~276e5b57f6e302c559ec1b5f37c9848d

Analysts' recommendations: PROCEPT BioRobotics Corporation

10-07	Barclays Initiates PROCEPT BioRobotics at Overweight With $30 Price Target	MT
08-05	Truist Adjusts Price Target on PROCEPT BioRobotics to $21 From $26, Maintains Hold Rating	MT
08-05	William Blair Downgrades PROCEPT BioRobotics to Market Perform From Outperform	MT
07-28	UBS Downgrades PROCEPT BioRobotics to Neutral From Buy, Cuts Price Target to $20 From $30	MT
07-06	Truist Downgrades PROCEPT BioRobotics to Hold From Buy, Lowers Price Target to $25 From $30	MT
06-24	Evercore ISI Initiates Coverage on PROCEPT BioRobotics With Outperform Rating, $30 Price Target	MT
06-11	PROCEPT BioRobotics Shares Drop After Downgrade From Leerink Partners	MT
06-11	Leerink Partners Downgrades PROCEPT BioRobotics to Market Perform From Outperform, Adjusts PT to $29 From $31	MT
03-06	Baird Initiates PROCEPT BioRobotics at Neutral With $30 Price Target	MT
02-26	Oppenheimer Downgrades PROCEPT BioRobotics to Perform From Outperform, Removes $60 Price Target	MT
02-26	BofA Downgrades PROCEPT BioRobotics to Underperform From Neutral, Price Target is $20	MT
12-18	Truist Securities Adjusts Price Target on PROCEPT BioRobotics to $47 From $50, Maintains Buy Rating	MT
12-08	PROCEPT BioRobotics has Large Market Opportunity, but Utilization Growth has Slowed, BofA Says	MT
25-09-02	Procept Offers Attractive Risk-Reward, Oppenheimer Says	MT
25-09-02	Oppenheimer Upgrades PROCEPT BioRobotics to Outperform From Market Perform, Price Target is $60	MT
25-08-07	Truist Lowers Price Target on PROCEPT BioRobotics to $64 From $70, Keeps Buy Rating	MT
25-07-15	Procept BioRobotics Awarded Category 1 Code in 2026 Medicare Proposal	MT
25-07-07	Oppenheimer Initiates PROCEPT BioRobotics at Market Perform	MT
25-04-24	Morgan Stanley Cuts Price Target on PROCEPT BioRobotics to $71 From $95, Keeps Overweight Rating	MT
25-04-11	Truist Cuts Price Target on PROCEPT BioRobotics to $70 From $90, Keeps Buy Rating	MT
25-02-26	Truist Securities Adjusts PROCEPT BioRobotics Price Target to $90 From $105, Maintains Buy Rating	MT
24-12-02	Morgan Stanley Initiates PROCEPT BioRobotics at Overweight	MT
24-11-14	Procept BioRobotics Shares Decline After Jefferies Initiates Coverage at Hold	MT
24-11-14	Jefferies Initiates PROCEPT BioRobotics at Hold With $95 Price Target	MT
24-10-29	Truist Securities Raises Price Target on PROCEPT BioRobotics to $105 From $95 After Q3 Beat, Reiterates Buy Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PROCEPT BIOROBOTICS CORPORATION					+9.61%
	ABBOTT LABORATORIES					+13.34%
	STRYKER CORPORATION					+16.32%
	MEDTRONIC PLC					+7.73%
	ESSILORLUXOTTICA					+21.16%
	CENCORA, INC.					+11.66%
	HOYA CORPORATION					+16.36%
	BECTON, DICKINSON AND COMPANY					-1.4%
	IDEXX LABORATORIES, INC.					+20.56%
	ALCON INC.					+26.66%
	Average					+14.20%
	Weighted average by Cap.					+13.93%